Roughly 50% of melanoma cases express a BRAF mutation (BRAF-MT) and may either be treated with a BRAF/MEK inhibitor combination or ICI therapy (Figure 2) [114,115,116,117,118,119,120,121,122]. This evidence concerns the gene BRAF and melanoma.